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Abstract
Early infection diagnosis as the cause of a patient’s systemic
inflammatory syndrome is an important facet of sepsis care
bundles aimed at saving lives. Microbiological culture provides the
main route for infection diagnosis but by its nature cannot provide
time-critical results that can impact on early management.
Consequently, broad-spectrum and high-potency antibiotics are
essential during the immediate management of suspected sepsis
in critical care but are associated with the development of drug-
resistant organisms and superinfections. Established molecular
laboratory techniques based on polymerase chain reaction (PCR)
technology can detect pathogen DNA rapidly and have been
developed for translation into a clinical diagnostic setting. In the
setting of sepsis in critical care, emerging commercial systems are
now available for the analysis of whole blood within hours, with the
presumed aim of adoption into the current care bundles. In this
review, we consider the importance of early infection diagnosis in
sepsis, how this is limited by culture approaches and how the
emerging PCR methods are showing promise in early clinical
observational studies. The strengths and weaknesses of culture
and PCR pathogen detection in whole-blood samples will be
highlighted and recommendations made for urgent appropriately
powered diagnostic validation studies in advance of clinical effec-
tiveness trials before these emerging PCR pathogen detection
techniques can be considered for adoption in clinical practice.
Importance of rapid infection diagnosis in
surviving sepsis
Sepsis is the clinical syndrome resulting from a host’s systemic
inflammatory response to infection and is a major international
health care problem. The Surviving Sepsis Campaign
promotes an important concept of early, goal-directed
management of sepsis as part of the evidence-based
guidelines aimed at saving lives [1]. At the core of these
guidelines are the early diagnosis of infection as a cause for
the patient’s systemic inflammatory response and the timely
administration of appropriate antimicrobial chemotherapy.
The consensus definitions of infection in critical care require
microbiological evidence of pathogens to make a probable
diagnosis (for example, Gram stain) or culture to confirm the
diagnosis [2]. The Surviving Sepsis Campaign guidelines
advocate obtaining at least whole blood and, where possible,
other supporting clinical samples for culture prior to the
administration of antibiotics, all achieved within 1 hour in a
patient with presumed severe sepsis [1]. Current opinion in
critical care favours the early use of antibiotics, guided by
local pathogen surveillance, usually of a broad spectrum and
high potency, that is equally applicable to all clinical settings
in patients with suspected severe sepsis [1]. There is
evidence showing that the correct initial choice of antibiotic
saves more lives than virtually any other intensive care unit
intervention [1,3-5]. This may require broad-spectrum cover
in the face of as-yet-unidentified infection because delaying
antibiotic therapy in sepsis has been shown to increase
mortality and morbidity [6,7]. Unfortunately, the widespread
use of broad-spectrum antibiotics is implicated in the emer-
gence of drug-resistant organisms and rising rates of
infection with Clostridium difficile and fungi. Therefore, early
de-escalation of antimicrobial agents is a key aim of
Surviving Sepsis Campaign guidelines in order to reduce
this problem [1].
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Use and limitations of blood culture in sepsis
diagnosis
Blood cultures have a central role in the detection of patho-
genaemia in patients with evidence of the systemic inflam-
matory response syndrome (SIRS), thus helping differentiate
SIRS and sepsis [1]. Positive results enable antibiotic therapy
to be rationalised once pathogen identification and antibiotic
sensitivities are known. Blood cultures are considered to
provide the clinical gold standard in the diagnosis of
bloodstream infections [2], and an established evidence base
for their appropriate use when assessing and treating
suspected sepsis now exists [1]. In addition, blood cultures
can have significant diagnostic value in settings for which the
establishment of a microbiological diagnosis is otherwise
difficult, particularly in deep-seated infections that would
otherwise require invasive procedures for samples to be
obtained for culture [2]. Surveillance data from blood cultures
also constitute an important epidemiological tool on which to
base empirical antimicrobial therapy [1].
While a number of clinical and technical factors may affect
the isolation of the infecting organism [8], the volume of
blood sampled is the most critical factor in the detection of
bloodstream infection. The number of organisms present in
adult bacteraemia is frequently low, often less than 10
colony-forming units per millilitre (CFU/mL) [9,10]. There is a
direct relationship between blood volume and yield, with an
approximately 3% increase in yield per millilitre of blood
cultured [10]. National standard laboratories in Europe
recommended that at least 20 to 30 mL of systemic blood be
cultured from adults [11], which is reinforced by the Surviving
Sepsis Campaign guidelines that promote at least two sets of
cultures, which may also include additional blood sampling
from established indwelling catheters to help delineate
catheter-related infection [1].
Contamination of blood cultures giving a ‘false-positive’ result
remains a significant problem that can limit diagnostic utility in
the critically ill and is closely associated with poor patient-
sampling techniques. Documented rates of contamination
vary considerably between institutions, from 0.6% to over
6%, and the interpretation of these rates continues to be
problematic [12]. Clearly, repeating blood culture sets
increases sample volume and pathogen yield in the setting of
bloodstream infection but is primarily recommended to assist
in the recognition of contamination [12].
Despite laboratory techniques aimed at neutralising anti-
microbial substances present in a blood sample, the
sensitivity of blood cultures decreases greatly when taken
after the initiation of antimicrobial therapy [13,14]. The use of
prophylactic antibiotics and antifungal agents in immuno-
compromised neutropenic patients, who have a high risk of
developing pathogenaemia and who may subsequently show
signs of SIRS, makes diagnosis challenging as blood cultures
remain negative in many cases [15]. Such patients are also at
considerable risk of acquiring infection caused by slow-
growing and fastidious organisms, including fungi, for which
blood cultures are poorly sensitive.
The detection and identification of microorganisms based on
traditional culture-based methods make time-critical decision-
making rather difficult because of the significant time lags
between patient sampling and results. This can take 2 to
3 days for bacteria and much longer for other fastidious
organisms, and as a consequence, the time required to prove
absence of infection by culture methods can exceed that of a
treatment course of antibiotics [16]. Therefore, although
blood cultures remain at the heart of the sepsis care
guidelines, emerging alternative technologies aimed at
complementing the deficiencies of culture, particularly related
to improving time-critical diagnostics, are being investigated.
Polymerase chain reaction approaches to the
diagnosis of pathogenaemia
Molecular methods based on polymerase chain reaction
(PCR) technology have been developed for infection diag-
nosis and pathogen identification. These methods offer a new
approach based on detection and recognition of pathogen
DNA in the blood, or indeed other clinical samples, with the
potential to obtain results in a much shorter time frame
(hours) than is possible with conventional culture. PCR-
based pathogen detection depends on the ability of the
reaction to selectively amplify specific regions of DNA,
allowing even minute amounts of pathogen DNA in clinical
samples to be detected and analysed. The DNA sequence
that is amplified is determined by the design of
oligonucleotide primers, short pieces of synthesised DNA
that bind to either end of the sequence and form the starting
point for DNA replication by DNA polymerase.
For bacterial pathogens, two basic approaches have been
taken in assay design, using either specific primers that
detect a particular organism or, more commonly, universal
primers that bind to conserved sequences in bacterial but not
human DNA. The latter approach has the potential to detect a
large number of bacterial species in a given sample. Assays
that are limited to the detection of a specific organism have
often been developed to address a specific clinical need (for
example, rapid confirmation of the presence of meningo-
coccoci in patients with meningitis) [17]. In most cases,
however, the detection of bloodstream infection requires
assays capable of detecting a broad range of pathogens
given that several microbial species may be involved,
including infections with multiple organisms. To achieve this,
the majority of studies have used primers targeting the 16S
rRNA gene, with a smaller number focusing on the 23S rRNA
gene, which also contains conserved sequences. Following
PCR of these regions, the pathogen species present can be
identified subsequently by sequencing of the amplified DNA
followed by phylogenetic analysis using widely available
nucleotide databases [18]. Since the 16S rRNA genesequence is ubiquitous in bacteria, this approach has the
potential to detect virtually any bacterial pathogen, although
some shortcomings have been identified [19]. As early as
1999, Cursons and colleagues [20] showed that PCR
directed against the 16S ribosomal region was effective in
detecting pathogenaemia in a cohort of critically ill patients,
although careful optimisation of pathogen DNA extraction
was necessary, particularly for the detection of Gram-positive
organisms. It was concluded that PCR was more sensitive
than conventional blood culture, with a significant proportion
of patients being PCR-positive and blood culture-negative.
Jordan and colleagues [21] used a similar approach to detect
sepsis in neonates but with the addition of pyrosequencing, a
technique that enables a more rapid identification of the
bacterial species by sequencing short fragments (approxi-
mately 30 bases) of the 16S rRNA.
The 23S rDNA region shows more sequence variation
between bacterial species than 16S, potentially making the
former more suitable for discriminating the different blood-
borne pathogens encountered in critical care. The few
studies that have targeted the 23S region show that it is
effective in detecting a range of bloodstream infections
[22,23]. More recently, the gene sequence between the 16S
and 23s regions, the so-called internal transcribed region,
has been targeted because it contains more variable regions
than either 16S or 23S, allowing even better discrimination of
bacterial species [24,25].
Perhaps the single most important advance in molecular
diagnosis of infection has been the application of real-time
PCR. In this technique, the products formed during PCR are
monitored continuously as the reaction progresses, using
either fluorescent dyes that bind nonspecifically to double-
stranded DNA or fluorescently labeled probes that bind to
specific sequences. The whole process of PCR amplification,
product detection and analysis is achieved in a single reaction
vessel. Furthermore, several sequence-specific probes with
different fluorescent reporters can be added to the reaction,
allowing simultaneous determination of multiple products.
This process is therefore ideally suited to infection diagnosis
in which a variety of pathogen species could be involved.
Another advantage of real-time PCR is that, unlike conven-
tional PCR, it offers the potential to quantify the amount of
pathogen DNA present in a clinical sample. Real-time PCR
has now been applied in a number of clinical pilot studies.
Jordan and Durso [26] recently described a real-time assay
based on 16S rDNA which was capable of detecting a range
of common pathogens encountered in neonatal sepsis, and
when the assay was applied to 85 blood samples from
culture-proven sepsis, they reported a 94% agreement.
Subsequently, a number of small studies have indicated the
analytical effectiveness of using real-time PCR to detect
infection in an adult intensive care setting [25,27-29],
although the clinical utility of such measurements requires
further evaluation.
The ability to rapidly detect the presence of antibiotic-
resistant organisms is an increasingly important consideration
in intensive care. Conventional antimicrobial susceptibility
tests require culture of the organism from the clinical sample
with a further delay of at least 24 to 48 hours before results
are available. Once the genetic differences that underlie drug
resistance in a particular species are known, it is feasible to
develop PCR assays able to rapidly identify resistant
organisms directly in clinical samples [30]. This approach has
been successfully applied to the detection of methicillin-
resistant Staphylococcus aureus (MRSA) in various clinical
samples with assays aimed at the mecA and femA genetic
elements that cause resistance. A study of tracheal aspirates
from mechanically ventilated patients showed concordance
between PCR and conventional culture in 57 out of 60
MRSA-positive samples [31]. Furthermore, of the three
discordant results (PCR-positive, conventional-negative), all
three were later shown to be MRSA-positive through
complementary bacteriological testing. Similarly, Louie and
colleagues [32] showed diagnostic sensitivity and specificity
of 99% and 100%, respectively, for PCR in a study of 306
patients with MRSA bacteraemia with PCR data available
within 3 hours. More importantly, it has now been shown that
the introduction of PCR screening for MRSA in critical care
has a significant impact on transmission rates, with an
associated relative risk reduction of 0.65 and a 95%
confidence interval of 0.28 to 1.07, in a cohort of 1,305
critically ill patients [33]. While PCR may be appropriate in
identifying resistance in specific organisms, it is unlikely in
general to be the most effective way of screening for drug
resistance given the hundreds of known resistance genes.
The use of other genetic techniques (such as DNA micro-
array) which allow simultaneous analysis of a large number of
drug-resistance genes in diverse bacteria is under investi-
gation [34].
Fungal infections are also targets for the development of
molecular diagnostic techniques. Infections with Aspergillus
and Candida species are increasingly important in intensive
care and are associated with high morbidity and mortality.
However, current diagnostic procedures like mycological
culture or microscopy require either long growth periods or
suffer from poor sensitivity. Several PCR assays aimed at
identifying specific fungal species have been developed,
although this approach has limitations given that in a
proportion of cases infections may be polymicrobial. A recent
review showed that, in the case of Aspergillus, most PCR
assays were targeting the two most prevalent types,
Aspergillus fumigatus and A. flavus, which represent only 2
out of the 20 or so Aspergillus species that have been shown
to cause opportunistic infections in humans [35]. Studies
comparing PCR methods with the enzyme-linked immuno-
sorbent assay (ELISA) test for Aspergillus antigen and other
markers used in the diagnosis of invasive pulmonary
aspergillosis have reported diagnostic sensitivity of 79% for
PCR compared with 58% and 67% for ELISA and other
Available online http://ccforum.com/content/13/4/217
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PCR compared with 97% for ELISA and 84% for the other
diagnostic tests, respectively. Importantly, results of PCR
were available more quickly than those of the other diagnostic
tests [35]. More recently, broad-range real-time PCR assays
for fungal species have been developed [36,37].
Schabereiter-Gurtner and colleagues [37] used a
combination of universal primers and group-specific probes
to identify 11 clinically relevant Aspergillus and  Candida
species in a range of clinical samples, including blood,
tracheal aspirates and cerebrospinal fluid. The assay was
able to detect fungal infections with high analytical sensitivity
(for example, 5 to 10 CFU/mL blood).
In terms of clinical utility in sepsis, the most effective PCR
approach would be one in which both bacterial and fungal
species could be detected and identified in a single assay.
Roche Diagnostics (Basel, Switzerland) has introduced the
SeptiFast™ platform following recent European regulatory
approval. SeptiFast™ is a commercial real-time PCR diag-
nostic kit that is designed to detect and identify 25 bacterial
and fungal species that make up greater than 90% of the
pathogens causing bloodstream infections in critical care,
with a sensitivity of between 3 and 30 CFU/mL [25]. To date,
there has been only limited published evidence of the clinical
utility of SeptiFast™. A recent study by Louie and colleagues
[38] in 200 patients with clinical suspicion of sepsis recruited
from a mixture of intensive care and general medicine acute
wards showed that SeptiFast™ detected more instances of
pathogenaemia than did blood culture, with results available
potentially within 6 hours. However, that study also reported
several false-negatives in which culture detected an organism
that was not present on the SeptiFast™ PCR panel, a
limitation of the current platform. Broadly similar findings with
SeptiFast™ have been reported in a group of haematology
patients with suspected sepsis [39]. A second commercial
system for diagnosis of bloodstream infection, SepsiTest™
(Molzym GmbH & Co. KG, Bremen, Germany), recently
gained European regulatory approval. This test takes a
different approach, using universal primers to report the
presence of a bacterial or fungal DNA in blood with species
identification relying on post-test sequencing of the products.
To date, there have been no published studies evaluating the
use of SepsiTest™ in a clinical setting.
Key issues in the application of polymerase
chain reaction to the diagnosis and
management of sepsis
The application of PCR techniques to detect and identify
pathogens has the potential to revolutionise the diagnosis
and management of sepsis. Unlike microbiological culture, a
PCR diagnosis confirming the absence or presence of a
pathogen, along with species identification, could be avail-
able to the clinician in a few hours. However, there remain a
number of unresolved questions about the interpretation of
PCR clinical data and the significance of circulating pathogen
DNA as a marker of infection. There are several possible
reasons for frequently reported so-called ‘false’ positives in
which PCR shows evidence of pathogen DNA in the absence
of culturable organisms. Given the sensitivity of the PCR
technique, it is important to rule out the possibility that a
‘false’ positive occurs as a result of environmental contami-
nation, although these events can be minimised by adoption
of strict procedures for sample collection and processing
[25]. PCR may also give a positive result in the absence of
intact pathogens since it does not distinguish between DNA
associated with viable bacteria and DNA originally from intact
bacteria in the circulation which have been destroyed as a
result of host immune responses and/or recent antibiotic
administration. Further studies are needed to monitor the
kinetics of bacteria DNA appearance and clearance from the
blood during infection and antibiotic treatment. It is important
to consider that ‘false’ positives may have biological
significance and provide information of diagnostic value. For
example, freely circulating pathogen DNA may be a biomarker
of infection at extracirculatory sites due to shedding of
pathogen DNA into the circulation. With this in mind, the
adoption of techniques that separate intact organisms in
blood, or other fluids, prior to DNA extraction [40] would
allow discrimination between the presence of DNA asso-
ciated with intact pathogens and free pathogen DNA. Such
DNA separation may help investigators to understand the
high rates of ‘false-positive’ PCR results in blood from
patients with suspected sepsis and potentially provide
valuable information on the broader infection phenotype in an
individual. In recognising the potential limitations of PCR for
detecting infection, it is also important to balance these
against uncertainties in the current ‘gold standard’ of micro-
biological culture.
Despite the significant potential benefits in reducing un-
necessary antibiotic use in critical care, there has been little
discussion so far regarding the value of a negative PCR result
from blood ruling out sepsis in patients who are subsequently
shown on culture to have no evidence of infection. However,
here again, careful validation of pathogen PCR is required
since instances of negative PCR results associated with
positive blood culture are reported, although these are
relatively infrequent and, in many cases, appear to be the
result of the organism’s not being included in the particular
PCR panel [41]. Similar considerations apply to the applica-
tion of PCR to other clinical samples such as sputum for the
diagnosis of nosocomial respiratory infections such as venti-
lator-associated pneumonia. However, additional sample-
specific issues may arise such as the high background levels
of commensal organisms likely to be present in the respiratory
tract which may make clinical interpretation of PCR data more
difficult.
Conclusions
There is real promise of rapid infection diagnosis in sus-
pected sepsis using PCR pathogen detection as evidenced
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Sepsis Campaign publications and by the early commerciali-
sation of these molecular laboratory techniques for applica-
tion in critical care. While culture techniques offer the best
practice today, limitations, particularly in terms of their time
constraints and their sensitivities in patients already exposed
to antibiotics, are significant. However, the promise of rapid
PCR-driven single-blood-sample diagnostics in this arena has
yet to be realised, and only a few peer-reviewed observational
studies using the emerging commercially available systems
have been published. Therefore, we have the opportunity now
to drive a thorough health technology assessment process of
the available PCR systems from laboratory diagnostic
validation through to appropriately powered, well-designed
clinical validation and effectiveness studies in populations of
critically ill patients who would most likely benefit. We
anticipate that, if PCR technologies prove to have acceptable
clinical diagnostic validity, subsequent clinical effectiveness
studies are most likely to prove cost-efficient when comparing
standard culture with PCR in delivering early antibiotic de-
escalation. Until such processes have been completed and
reported, we cannot recommend technology adoption. We
also believe that a systematic approach to the investigation of
pathogen DNAemia during critical illness will help delineate
patient phenotypes in the SIRS/sepsis spectrum and provide
a firmer understanding of the biology of pathogen DNA that
underpins rapid PCR-based diagnostics. Furthermore, the
feasibility of determining antibiotic sensitivities at a gene level
for a range of pathogens associated with sepsis remains to
be investigated but should not delay the assessment of the
currently available commercial platforms aimed at pathogen
detection and identification.
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